3 Biotech Companies that Remain Attractive

Published Thu, 03 Sep 2015 10:30 CET by DividendYields.org

One of the fastest-developing industries in the financial markets is biotechnology. One of the biggest challenges that the biotech companies face is high R&D costs and the need for a steady revenue stream to finance their operating activities while waiting for FDA drug approval. This makes them heavily reliant on the public markets to finance the development and manufacturing of innovative medicines.
On the upside, the biotech sector remains attractive for retail investors in spite of its high-risk. According to McKinsey, in December 2014, biotech companies accounted for the 20% of the entire pharma market with global revenues of $163 billion, while their annual growth rate was +8%, double than conventional pharmaceutical companies.
This article summarizes three mid and large-cap stocks trading in the Healthcare sector of the Biotechnology industry. Having revisited their strategies and focusing on R&D, all three companies are expected to continue to grow at a fast rate, paying higher dividends to retail investors.

Baxter, Bio-Techne and Gilead Sciences Price Performance vs. S&P 500 Year over Year Graph
Baxter International (NYSE: BAX) engages in the development, manufacturing and marketing of products for the cure of immune diseases as well as chronic and severe medical conditions. The most important milestone of the Deerfield-based biotech company in July 2015 was the corporate spin-off of the bioscience sector and the creation of Baxalta (NYSE: BXLT), a separate company that develops medicines for rare diseases and focuses on gene therapy. Baxter’s D/E ratio is below 2, however, the company is dealing with debt. Q2 2015 R&D spending increased 1%, reaching $292 million, however BAX has moved $5 billion of debt to the Baxalta balance sheet and has successfully dealt with another $1.1 of convertible bonds, thus lowering interest expenses to $30 million from $42 million (YoY -28.6%). The company’s decision to bring new products to the market over the next years, aiming to improve its positioning and long-term performance, is expected to leave room for a higher dividend given its low payout ratio. A beta of 0.31 makes BAX a safe investment.

Bio-Techne Corp. (Nasdaq: TECH) is a Minneapolis-based biotech company operating in the development, manufacturing and sale of biotech products and clinical diagnostic controls globally. The acquisition in June of Cliniqa Corporation, a company focussing on the clinical diagnostic market, is expected to boost TECH’s clinical control portfolio and improve its growth as Cliniqa has a proven track record of cash-oriented growth. In addition, the company is looking to go bigger in China, believing there is growth in the Chinese market. On the upside, TECH’s acquisition strategy is expected to create profitable opportunities that could boost profitability. On the downside, sharp fluctuations in the foreign exchange rates have reduced inventories in overseas markets, namely Japan and the Pacific, thus raising a red flag for TECH. The EPS of $1.28 is expected to average at $4.27 over the next 4 years, whereas the 5-years long-term annual growth is expected 12.5%. TECH’s D/E ratio of 0.23, far below 2, indicates that the company is not relying on debt financing, which is also reflected in the low payout ratio. A beta of 0.72 suggests a safe investment.

Name Price ($) 52 wk low 52 wk high 52 wk low % 52 wk high % Market Cap ($ b) P/E D/E Beta Payout Ratio
Baxter 37.23 34.50 43.44 7.91% -14.30% 20.31 9.30 1.44 0.31 12%
Bio-Techne 91.95 86.01 114.56 6.91% -19.74% 3.42 31.82 0.23 0.72 44%
Gilead Sciences 101.49 85.95 123.37 18.08% -17.74% 148.95 10.71 0.84 0.86 18%

Gilead Sciences (Nasdaq: GILD), headquartered in Foster City, CA, engages in the development and sale of innovative medicines for HIV and chronic hepatitis, but also cardiovascular and respiratory diseases and cancer. Q2 2015 U.S revenue reported 16% YoY growth reaching $5.6 billion, while European revenue reported 50% YoY growth in spite of the foreign exchange headwinds. The growth was driven by the launch of Harvoni hepatitis medicine across various markets around the world, the sustained growth of Sovaldi hepatitis medicine outside the U.S. and increased sales of GILD’s newer HIV single-tablet regimen. GILD’s highly differentiated product line and addition of new patients to its treatment program are both expected to improve its position and boost its growth. Analyst consensus estimates an average annual growth of 13.5% over the next five years and an average EPS of $11.26 up to 2016 (current EPS $9.53). A beta of 0.84 suggests a safe investment, leaving for a higher dividend (currently at $1.72) and long-term value for investors.
Stock name Dividend Yield
Gilead Sciences 3.85
Baxter International 0.98
Techne 0.64

Articles featuring Gilead Sciences (GILD):

Undervalued Growth And Dividend Growth In Health Technology: Part 11

Introduction Although many Health Technology Sector companies have significantly outperformed the market on a long-term basis, they have significantly underperformed the market since the beginning of 2015. With only a few minor exceptions, this is true for most companies, especially the pharmaceutical companies, operating in this sector. On the other hand, there are several examples where operating performance has been exemplary even though stock price performance has been dismal. In my... Read more

Your 55 March Quarter NASDAQ Dividend Dogs By Yield, Upside And Net Gains

Actionable Conclusions (1-10): Brokers Forecast 10.66% To 30.28% Net Gains From NASDAQ March Top Ten Six of ten top yield NASDAQ dividend stocks were identified as being among the top ten net gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the chart below). So, our yield-based forecast for NASDAQ 54 divi-dogs was graded by Wall St. brokers as 60% accurate. Source: YCharts Projections based on estimated dividend returns from $1000... Read more

Here's 68 Top S&P 500 Stocks For Yield, Gains & Upside In March

Actionable Conclusions (1-10): Analysts Estimated 10.25% To 24.83% Net Gains For Ten S&P 500 Dogs Into March 2020 Five of ten top S&P 500 dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the chart below). Thus, this yield-based forecast for S&P 500 dogs was graded by Wall St. Wizards as 50% accurate. Projections were based on estimated dividends from $1000 invested in each... Read more

Gilead Sciences, Inc.: Consider a Biotech Stock for Dividends?

A Top Dividend Stock From an Unlikely Industry Income investors are not a fan of uncertainty, which is part of the reason why they donít look at biotech stocks that often. For some biotech companies, their stocksí appeal depends critically on the result of certain clinical trials. If you are a long-term income investor, you probably donít want to be kept up at night by news like that. Plus, biotech firms have to pour big money into research and development. So even if they are... Read more

2 Dividend Blue-Chips Set To Soar And 1 You Should Ignore

My new Deep Value Dividend Growth Portfolio or DVDGP (beating the market by 9% so far) owns 70 companies. However, that level of diversification isn't usually optimal for most investors who aren't professional analysts (I research over 200 companies per year for Simply Safe Dividends). Rather most investors are better off owning 20 to 50 companies, depending on their ability to follow companies at least on a yearly basis (to make sure the bullish theses are intact). Thus, when deciding... Read more